Business Context and Reporting Period
This Form 8-K filing by Karyopharm Therapeutics Inc. reports on events occurring on January 20, 2017. The filing details Item 5.02, covering the departure, election, or appointment of officers and directors, specifically focusing on new option grants and compensation adjustments for executive leadership.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused exclusively on executive compensation and equity awards.
Material Changes and Compensation Details
On January 20, 2017, the Compensation Committee and Board of Directors approved the following material changes to executive compensation:
Option Grants
- Grant Date: January 20, 2017
- Exercise Price: $10.39 per share (Fair Market Value on grant date)
- Vesting Schedule: 25% on the first anniversary, with the remainder vesting in equal increments over the subsequent 36 months.
- Recipients and Share Counts:
- Michael G. Kauffman (CEO): 250,000 shares
- Sharon Shacham (President and CSO): 250,000 shares
- Justin A. Renz (EVP, CFO): 100,000 shares
- Christopher B. Primiano (SVP, Operations): 118,000 shares
- Ran Frenkel (Chief Development Operations Officer): 100,000 shares
Salary and Bonus Adjustments
The company approved 2016 performance-based bonuses and new 2017 annual base salaries effective January 1, 2017:
| Name & Title | 2016 Bonus | 2017 Annual Salary | 2017 Target Bonus % |
|---|---|---|---|
| Michael G. Kauffman, CEO | $247,200 | $530,500 | 60% |
| Sharon Shacham, President & CSO | $166,000 | $435,000 | 50% |
| Justin A. Renz, EVP & CFO | $114,100 | $371,000 | 40% |
| Christopher B. Primiano, SVP | $122,000 | $390,000 | 40% |
| Ran Frenkel, Chief Dev. Ops. | $100,800 | $341,000 | 40% |
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, operational outlook, risk factors, or contingencies. The document is strictly limited to reporting the specific compensation actions taken on the filing date.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2013 Stock Incentive Plan to assess remaining capacity for future grants.
- Confirm the impact of the $10.39 exercise price relative to the company's current stock price to evaluate the intrinsic value of the grants.
- Review the specific performance metrics tied to the 2016 bonuses and the 2017 target bonus percentages to understand payout conditions.
- Check subsequent filings for any changes to the vesting schedule or acceleration clauses related to these options.